Abstract bekijken

Deze abstract is toegekend aan sessie OB Free papers 4 - Glaucoma
TitelFRO - Can peroperative bevacizumab (Avastin) improve trabeculectomy outcome? A prospective, randomized, placebo-controlled study
DoelGlaucoma surgery fails in 30% due to excessive scar formation of the constructed channel. Our group found that vascular endothelial growth factor (VEGF) is upregulated in the aqueous humor of glaucoma patients and postoperatively in a rabbit model for trabeculectomy, that VEGF stimulates fibroblast proliferation in vitro whereas bevacizumab can inhibit their growth, and that a single peroperative intracameral injection of bevacizumab improves the surgical outcome of trabeculectomy in a rabbit model. Based on these findings, we set up a clinical trial to study the potential of bevacizumab as an anti-scarring agent after trabeculectomy.
MethodesThis is a prospective, randomized, placebo-controlled, double-blinded experimental study. The effect of peroperative administration of 50 µl of bevacizumab (25mg/ml) on intraocular pressure, bleb characteristics, as well as number of postoperative IOP-lowering medications and surgical interventions is investigated. Patients with primary open-angle glaucoma (POAG) and normal tension glaucoma (NTG) who are scheduled for primary trabeculectomy are included.
ResultatenInclusions started on April 2009. Based on a priori calculations we need to include 124 patients. The inclusions will be accomplished in September 2010.
ConclusieThis study will provide evidence on effectiveness and safety of single administration of bevacizumab during trabeculectomy to reduce the risk of surgical failure, avoiding or reducing the need for long-term medication use or secondary surgical intervention.
Auteur 1
NaamVANDEWALLE
InitialenE
InstituutULZ
StadLeuven
Auteur 2
NaamZeyen
InitialenT
InstituutUZL
StadLeuven
Auteur 3
NaamSpielberg
InitialenI
InstituutDep of ophthalmology
StadRotterdam
Auteur 4
NaamStalmans
InitialenI
InstituutUZL
StadLeuven
top ^